The QualityStocks Daily Thursday, April 20th, 2023

Today's Top 3 Investment Newsletters

Tiny Gems(AUGX) $3.4000 +88.89%

QualityStocks(UIHC) $2.6800 +62.42%

SmallCapRelations(CNSP) $2.6200 +48.02%

The QualityStocks Daily Stock List

United Insurance Holdings (UIHC)

Zacks, MarketBeat, StreetAuthority Daily, StreetInsider, QualityStocks, TopStockAnalysts, The Street, RedChip, Dividend Opportunities, InvestorPlace, Marketbeat.com, Daily Trade Alert, Market FN, Barchart, Real Pennies, The Best Newsletters and Money Wealth Matters reported earlier on United Insurance Holdings (UIHC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

United Insurance Holdings Corp. (NASDAQ: UIHC) (FRA: 0UI) is a property and casualty insurance holding firm that services, writes and sources casualty insurance policies and commercial and residential personal property.

The firm has its headquarters in St. Petersburg, Florida and was incorporated in 1999. The firm primarily serves clients in the United States.

The company operates through its subsidiaries, which include United Property & Casualty Insurance Company, its insurance subsidiary. Its other subsidiaries include UPC Re, which offers a portion of the reinsurance protection brought by its insurance affiliate Skyway Claims Services LLC, which offers services to its insurance affiliate, and United Insurance Management L.C., which operates as the managing general agent and manages almost all aspects of the insurance subsidiary’s business.

The enterprise provides dwelling fire policies and liability, content and structure coverage for condominium unit owners, renters and single-family homeowners. It also provides cyber security and inland flood insurance, and identity theft, equipment breakdown and flood policies. In addition to this, it offers commercial multi-peril property insurance for residential condo associations. The enterprise distributes and markets its products via a network of independent agencies in Texas, South Carolina, Rhode Island, North Carolina, New York, New Jersey, Massachusetts, Louisiana, Hawaii, Georgia, Florida and Connecticut.

The firm is focused on achieving strong underwriting profit and its transition plan, which will facilitate an increase in reinsurance spend and involves increasing quota share of protection, which will decrease volatility and de-stress capital in both its personal line and commercial businesses. This may help bring in more investors into the firm.

United Insurance Holdings (UIHC), closed Thursday's trading session at $2.68, up 62.4242%, on 15,950,598 volume. The average volume for the last 3 months is 33.172M and the stock's 52-week low/high is $0.2921/$3.48.

Aethlon Medical (AEMD)

Tip.us, Investor Ideas, QualityStocks, StockMarketWatch, Red Chip, Streetwise Reports, OTCPicks, PennyStocks24, BUYINS.NET, MarketClub Analysis, MarketBeat, TraderPower, FeedBlitz, TradersPro, MicroCap Gems, AllPennyStocks, SmallCapVoice, StreetInsider, RedChip, Clutch Investments, Pennybuster, PricelessPennyStocks, PennyStockRumors.net, Stock Castle, Trading Concepts, BestStockChoice, TopPennyStockMovers, The Online Investor, DrStockPick, Faisam Trader, StockBlogs, INO Market Report, PennyOmega, Investing Futures, InvestorPlace, InvestorsUnderground, SmallCapStockPlays, SmallCap Network, Nebula Stocks, PennyTrader Publisher, WallStreet Advisors, Actual Gains and Investing Daily reported earlier on Aethlon Medical (AEMD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Aethlon Medical Inc. (NASDAQ: AEMD) (FRA: EJU) is a medical technology firm that is engaged in the development of products that help in diagnosing and treating organ and life threatening ailments in the U.S.

The firm has its headquarters in San Diego, California and was incorporated in May 1998 by James A. Joyce. It is a part of the scientific and technical instruments manufacturing industry and operates in the health care industry, under the medical equipment and devices sub-industry.

The company is party to a collaboration agreement with the University of Pittsburgh which entails research on neck and head cancers. It operates through the ESI and Aethlon segments. The latter segment is involved in diagnostic business activities while the former segment deals with therapeutic business activities.

The enterprise offers a platform that develops medical equipment to target the selective removal of ailment-promoting particles from an individual’s circulatory system, known as ADAPT. Its product pipeline is made of an exosomal biomarker candidate known as TauSome, which diagnoses chronic traumatic encephalopathy in people. In addition to this, the enterprise also develops a clinical-stage immunotherapeutic device known as the Aethlon Hemopurifier, which removes life-threatening viruses and exosomes from the body’s circulatory system. These exosomes aid in the progression of infectious viral pathogens like Hepatitis C and HIV as well as cancer.

The firm recently published case studies of 2 coronavirus patients who were treated with its Hemopurifier, with its CEO noting that their device may play a crucial role in filtering out exosomes, adding that their device was able to clear the SARS-CoV-2 virus from both patients’ bloodstream. The device’s success in treating both patients may bring in more investors into the firm and push share prices higher.

Aethlon Medical (AEMD), closed Thursday's trading session at $0.59, up 40.4762%, on 34,079,565 volume. The average volume for the last 3 months is 2.595M and the stock's 52-week low/high is $0.225/$2.46.

Matinas BioPharma Holdings (MTNB)

QualityStocks, MarketBeat, StockMarketWatch, TraderPower, BUYINS.NET, InvestorPlace, Marketbeat.com, Stock News Now, Zacks, StreetInsider, The Online Investor, SmallCapVoice, Schaeffer's, Tiny Gems, Trades Of The Day, Wall Street Mover, Wealth Insider Alert, FreeRealTime and Stock News reported earlier on Matinas BioPharma Holdings (MTNB), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) (FRA: 6LG) is a clinical-stage biopharmaceutical firm that is focused on the discovery and development of treatments for various indications.

The firm has its headquarters in Bedminster, New Jersey and was incorporated in May 2013 by Jerome D. Jabbour. It operates as part of the pharmaceutical and medicine industry, in the biotech and pharma sub-industry, under the health care sector. The firm has three companies in its corporate family and serves consumers in the United States.

The company is focused on enabling the delivery of life-changing medications using its lipid nano-crystals platform technology. Its technology encapsulates proteins, peptides, vaccines, oligonucleotides, small molecule drugs and other medications, making them orally bioavailable, less toxic, more tolerable and safer. The company is party to a feasibility collaboration with Genentech Inc., which entails the development of oral formulations; and research collaborations with ViiV Healthcare for the development and evaluation of formulations for antiviral drugs, as well as NINDS (National Institute of Neurological Disorders and Stroke), which entails the development of new treatments for HIV.

The enterprise's product pipeline is made up of an orally administered formulation dubbed MAT2501 which has concluded phase 1 clinical trials evaluating its effectiveness in treating intracellular bacterial infections and different types of multidrug-resistant gram negative infections and multidrug-resistant bacteria, which includes non-tuberculosis mycobacterium infections. It also develops an oral amphotericin B formulation known as MAT2203 which has been developed to prevent invasive fungal infections. The formulation is currently in phase 2 clinical trials.

The company recently announced positive safety and effectiveness data for its MAT2203 phase 2 trial. The formulation has been found to be effective in clearing fungal organisms. The success and eventual approval of the drug will be beneficial to patients and help bring in more investors into the company.

Matinas BioPharma Holdings (MTNB), closed Thursday's trading session at $0.715, up 17.2131%, on 2,602,264 volume. The average volume for the last 3 months is 70,868 and the stock's 52-week low/high is $0.389/$0.94.

Worksport Ltd (WKSP)

QualityStocks, MarketBeat, InvestorPlace, TradersPro and Broad Street reported earlier on Worksport Ltd (WKSP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Worksport Ltd. (NASDAQ: WKSP) is focused on designing, manufacturing and distributing tonneau covers, which are aftermarket accessories that offer protection for cargo and security to owners of personal pickup trucks.

The firm has its headquarters in Vaughan, Canada and was incorporated in 2003, on April 2nd. Prior to its name change in May 2020, the firm was known as Franchise Holdings International Inc. It operates as part of the auto parts industry, under the consumer cyclical sector. The firm serves consumers in the United States and Canada.

The company is focused on growing its market share through innovation in the clean tech and auto forest sectors. It seeks to capitalize on consumer mindset shifts toward clean energy integration with its hydrogen-based technology and solar solutions. The company is party to a collaboration agreement with Greatcell Energy Pty Ltd.

The enterprise provides TC (tough cover) and SC (soft cover) tonneau covers, which include a thin aluminum tri-cover panel with a core coated in a black scratch-resistant and durable powder coating dubbed TC3; a tri-fold cover which has been designed to protect cargo from debris and moisture known as SC3; and SC3pro, which allows operators to open the covers by pulling a release cable. It also develops a solar cover tonneau dubbed TerraVIS, which provides truck owners with rechargeable portable power. The enterprise distributes its products via online retail channels and wholesalers.

The firm, which is transitioning to manufacturing in North America from manufacturing in China, remains focused on building its inventory and improving its sales and manufacturing practices. This will bring in additional revenue and create value for its shareholders which will be good for its revenues as well as its growth.

Worksport Ltd (WKSP), closed Thursday's trading session at $1.53, up 13.3249%, on 73,312 volume. The average volume for the last 3 months is 709,999 and the stock's 52-week low/high is $0.95/$3.50.

Adverum Biotechnologies (ADVM)

MarketBeat, MarketClub Analysis, StockMarketWatch, BUYINS.NET, StreetInsider, Marketbeat.com, Schaeffer's, Trades Of The Day, QualityStocks, Daily Trade Alert, TradersPro, TopPennyStockMovers, The Street and InvestorPlace reported earlier on Adverum Biotechnologies (ADVM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Adverum Biotechnologies Inc. (NASDAQ: ADVM) (FRA: AVU) is a clinical stage gene therapy firm that is engaged in the development of gene therapy product candidates for the treatment of rare and ocular ailments.

The company is based in Redwood City, California and was incorporated in 2006, on July 17th by Steven Daniel Schwartz, Mitchell H. Finer, Thomas W. Chalberg Jr. and Mark S. Blumenkranz. It was formed after a merger between Annapurna Therapeutics and Avalanche Biotechnologies in May 2016.

The firm mainly generates its revenue through collaboration, research and license agreements with various strategic partners. It is party to license and collaboration agreements with Virovek, Lexeo, GenSight, Cornell University and the University of California. It focuses on the treatment of juvenile x-linked retinoschisis, color vision deficiency, severe allergy, friedreich’s ataxia, hereditary angioedema and alpha-1 antitrypsin deficiency.

Its product pipeline is made up of a gene therapy intravitreal injection dubbed ADVM-022 which has been indicated for the treatment of chronic retinal ailments that include diabetic macular edema and wet age-related macular degeneration. It has been designed to decrease the treatment burden of anti-VEGF injections and deliver long-term durability.

The firm will be making some major modifications to their programs after an unexpected occurrence in its clinical trial which resulted in vision loss in a patient. While the future of the firm is uncertain due to this setback, many are hopeful that this mishap will not happen again, especially given that the lead candidate is being developed to meet a previously unmet need, which that has the potential to be beneficial to lots of patients.

Adverum Biotechnologies (ADVM), closed Thursday's trading session at $1, up 8.6957%, on 709,999 volume. The average volume for the last 3 months is 246,928 and the stock's 52-week low/high is $0.531/$1.82.

Trevi Therapeutics (TRVI)

MarketClub Analysis, QualityStocks and MarketBeat reported earlier on Trevi Therapeutics (TRVI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Trevi Therapeutics Inc. (NASDAQ: TRVI) is a clinical-stage biopharmaceutical firm that is engaged in developing and commercializing therapies for the treatment of severe neurologically mediated conditions.

The firm has its headquarters in New Haven, Connecticut and was incorporated in March 2011 by Jennifer L. Good and Thomas R. Sciascia. It serves patients in the United States.

The company is party to a license agreement with Rutgers, which involves the development and commercialization of products that incorporate nalbuphine for any human or animal use. It is also party to a license agreement with Endo Pharmaceuticals Inc., which entails the development and commercialization of products that incorporate nalbuphine hydrochloride in their formulation.

The enterprise develops an investigational therapy known as Haduvio, for the treatment of severe neurologically mediated conditions that target the peripheral and central nervous systems. Haduvio is an oral extended release nalbuphine formulation. Nalbuphine has a dual mechanism of action, acting as both an agonist to the kappa opioid receptor and an antagonist to the body’s mu opioid receptor. The formulation is undergoing phase 2b/3 clinical trials, evaluating its effectiveness in treating chronic kidney disease-associated with pruritus, chronic pruritus, levodopa-induced dyskinesia in patients with Parkinson’s disease and chronic cough in patients suffering from idiopathic pulmonary fibrosis. These indications share a common pathophysiology which is mediated through opioid receptors in the peripheral and central nervous systems.

The firm is focused on accelerating the development of its Haduvio therapy for the treatment of idiopathic pulmonary fibrosis, which currently has no approved therapy. The success and approval of this formulation will not only benefit patients suffering from this indication but also bring in more investors into the firm, which will positively impact its growth.

Trevi Therapeutics (TRVI), closed Thursday's trading session at $2.72, up 10.5691%, on 246,928 volume. The average volume for the last 3 months is 338,198 and the stock's 52-week low/high is $1.43/$4.6834.

Tutor Perini (TPC)

Zacks, Investors Alley, StreetInsider, Kiplinger Today, BestOtc, CRWEFinance, CRWEPicks, CRWEWallStreet, StockHotTips, PennyToBuck, PennyOmega, DrStockPick, Marketbeat.com, Top Pros' Top Picks, MarketBeat, Barchart, StockMarketWatch, The Street, Daily Trade Alert, QualityStocks, Stockhouse, InvestorPlace, Investing Futures, FreeRealTime, The Wealth Report, TheStockAdvisors, BUYINS.NET and Trades Of The Day reported earlier on Tutor Perini (TPC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Tutor Perini Corporation (NYSE: TPC) (FRA: PE2) is a construction firm that is engaged in the provision of diversified general contracting, construction management and design-build services to public agencies and private customers.

The firm has its headquarters in Sylmar, California and was incorporated in 1894 by Bonfiglio Perini. Prior to its name change in May 2009, the firm was known as Perini Corporation. It operates as part of the engineering and construction industry, under the industrials sector. The firm serves consumers around the globe, generating most of its revenue from the United States.

The enterprise operates through the Civil, Specialty Contractors and Building segments. The Civil segment is engaged in the public works construction and the replacement and reconstruction of infrastructure; and provides civil contracting services, including construction and rehabilitation of bridges, highways, mass-transit systems, tunnels, military defense facilities, and water management and wastewater treatment facilities. It also offers foundation, drilling, and excavation support for bridges, shoring, roads, piers, and highway projects. The Specialty Contractors segment offers mechanical, electrical, plumbing and fire protection systems, as well as heating, ventilation, and air conditioning services (HVAC) for civil and building construction projects in commercial, industrial, mass-transit and hospitality and gaming end-markets. It also provides pre-construction planning and project management services. On the other hand, the Building segment provides various services in different specialized building markets, such as hospitality and gaming, health care, transportation, commercial offices, sports and entertainment, government facilities, education, biotech, pharmaceutical, correctional facilities and technology.

The company’s subsidiary, Lunda Construction Co., was recently awarded millions in funding by the Minnesota Department of Transportation for Repairs to the I-494 Bridge over the Minnesota River. This move will open it up to new growth and investment opportunities.

Tutor Perini (TPC), closed Thursday's trading session at $5.3, off by 3.6364%, on 348,552 volume. The average volume for the last 3 months is 129,542 and the stock's 52-week low/high is $5.23/$10.83.

Luokung Technology (LKCO)

TradersPro, StockMarketWatch, The Online Investor, Schaeffer's, PoliticsAndMyPortfolio, INO Market Report and BUYINS.NET reported earlier on Luokung Technology (LKCO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Luokung Technology Corp (NASDAQ: LKCO) is a company offering location-based services and mobile application products for long distance rail travelers.

The firm has its headquarters in Beijing, China and was incorporated in 2009, on October 27th. It operates as part of the software-application industry, under the technology sector. The firm serves consumers in the People’s Republic of China.

The enterprise’s offerings include its Luokuang mobile application, which offers business to customer (B2C) location-based services; and SuperEngine, that provides business to business (B2B) and business to government (B2G) services in connection with spatial-temporal big data processing. It also offers Luokung software development kits and application-programming interfaces, which provide spatial-temporal big data analysis and customized maps to software and mobile application developers; and spatial temporal indexing cloud service, a data-level virtualization technology. In addition to this, the enterprise provides information SuperEngine that includes the server engine, which enables it to manage, store and index the spatial temporal big data on the server side; and Web graphics image engine that supports transmission of graphics images, as well as display and edge computing for multi-terminal and cross-platform use. Further, the enterprise offers a spatial temporal cloud platform, which provides cloud services, including data resource, data storage and platform support services, as well as supports users to aggregate multi-source spatial data, map services, and Internet of Things streaming data; autonomous driving enabling services; and HD Map, an infrastructural component in smart transportation, autonomous driving, and smart cities.

The company recently signed a shares subscription agreement with China Orient Smart Ecotech Investment Group Ltd, a move that will positively influence investments into the company as well as boost its overall growth.

Luokung Technology (LKCO), closed Thursday's trading session at $1.69, up 3.0488%, on 130,779 volume. The average volume for the last 3 months is 145,703 and the stock's 52-week low/high is $1.47/$18.45.

MGO Global (MGOL)

QualityStocks, Breaking Stock Reports and 247 Market News reported earlier on MGO Global (MGOL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

MGO Global Inc. (NASDAQ: MGOL) is a lifestyle brand portfolio firm that is involved in fashion design, brand development and management, sourcing and manufacturing, licensing, IP protection, corporate finance, consumer engagement and experience, ecommerce, and retail sales and marketing activities related to the Lionel Messi brand.

The firm has its headquarters in Fort Lauderdale, Florida and was incorporated in 2018. It operates as part of the advertising agencies industry, under the communication services. The firm serves consumers around the globe.

The company is focused on creating fresh, modern and compelling product and apparel brands aligned with and inspired by the personal styles, values and aspirations of its valued brand partners. It has one reportable segment, which sells a range of products under the soccer legend Lionel Messi’s lifestyle brand, Messi Brand. The company primarily operates through the MGOTEAM 1 LLC subsidiary.

The enterprise’s products include t-shirts and sweatshirts, polos, pants and jackets for men; and t-shirts for women and kids, as well as graphic beach towels, bathrobes, posters, keychains and rugs. The Messi Brand sells their products under their website www.themessistore.com. It also offers a range of brands, including Tommy Hilfiger, J Brand, Fila, GUESS, Burberry, True Religion and Brooks Brothers, among others.

The company recently announced its latest financial results, which show increases in its revenues. It remains focused on expanding its brand portfolio and accelerating growth of its business. This will encourage more investments into the company and generate shareholder value.

MGO Global (MGOL), closed Thursday's trading session at $0.94, off by 5.6698%, on 149,910 volume. The average volume for the last 3 months is 126,213 and the stock's 52-week low/high is $0.92/$16.61.

ECARX Holdings (ECX)

Stockhouse and Money Wealth Matters reported earlier on ECARX Holdings (ECX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

ECARX Holdings Inc. (NASDAQ: ECX) is a global mobility-tech firm that is focused on the development of software and hardware solutions for the development of connected, automated and electrified mobility.

The firm has its headquarters in Shanghai, China and was incorporated in 2017 by Ziyu Shen and Eric Li. It operates as part of the auto parts industry, under the consumer cyclical sector. The firm primarily serves consumers in the People’s Republic of China.

The company is focused on partnering with OEMs to reshape the automotive landscape as the industry transitions to an all-electric future. As OEMs develop new vehicle platforms from the ground up, it is developing a full-stack solution to help continuously improve the in-car user experience. The company continues to shape the interaction between individuals and vehicles by rapidly advancing the technology at the heart of smart mobility.

The enterprise’s core products include infotainment head units (IHU), vehicle chip-set solutions, digital cockpits, a core operating system and integrated software stack. It mainly serves customers such as original equipment manufacturers (OEMs) and tier 1 automotive suppliers.

The company, which is set to announce its latest financial results, remains committed to advancing technology for smart mobility and becoming one of the top players in the global automotive industry. This will not only increase integration into millions of cars and bring in additional revenues but also extend the company’s reach globally while generating value for its shareholders.

ECARX Holdings (ECX), closed Thursday's trading session at $5, off by 4.0307%, on 126,319 volume. The average volume for the last 3 months is 2,700 and the stock's 52-week low/high is $3.0201/$11.00.

XCana Petroleum (XCPT)

We reported earlier on XCana Petroleum (XCPT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

XCana Petroleum Corporation (OTC: XCPT) is an oil and gas firm that is focused on exploiting gas and oil reserves.

The firm has its headquarters in Dallas, Texas and was incorporated in 1980. Prior to its name change in May 2007, the firm was known as Cana Petroleum Inc. It operates as part of the shell companies industry, under the financial services sector. The firm serves consumers around the globe.

The company has 3 wholly owned or controlled operating subsidiaries in the United States and Colombia. Global DataTel de Colombia S.A. is a subsidiary that is made up of 4 acquired firms in Colombia. These firms are involved in the computer system business. On Line Latin America, S.A. and eHOLA.com, Inc. are in the internet service business.

The enterprise mainly exploits natural gas and oil reserves in the Western Canadian Sedimentary basin. It is also, through its subsidiaries, engaged in computer system integration business; offering Microsoft Solutions; reselling telecommunications products and services; reselling midrange and personal computer systems, and IBM's operating system software and utilities in Colombia. In addition to this, the enterprise provides dial-up internet services to consumers and businesses in Bolivia, Argentina, Chile, Brazil, El Salvador, Colombia, Guatemala, Ecuador, Paraguay, Mexico, Venezuela, Peru and the United States.

The firm remains committed to improving its global consumer reach and generating additional revenues for the firm, in addition to encouraging more investments into the firm and creating value for its shareholders.

XCana Petroleum (XCPT), closed Thursday's trading session at $0.2658, even for the day. The average volume for the last 3 months is 5.76M and the stock's 52-week low/high is $0.0034/$0.495.

QuantumScape Corp. (QS)

InvestorPlace, Schaeffer's, StocksEarning, MarketClub Analysis, StockEarnings, The Street, QualityStocks, The Online Investor, MarketBeat, Daily Trade Alert, Cabot Wealth, Top Pros' Top Picks, TipRanks, Zacks, Trades Of The Day, Atomic Trades, wyatt research newsletter, INO Market Report, GreenCarStocks, Green Energy Stocks, CNBC Breaking News and BUYINS.NET reported earlier on QuantumScape Corp. (QS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Walmart is planning to equip thousands of Sam’s Club and Walmart locations in the United States with new quick-charging points for electric vehicles by 2030. This plan would dramatically raise the number of chargers at Walmart locations from the current 1,300 available at a minimum of 280 stores to a significantly larger number.

Walmart aims to satisfy the requirements of its consumers and members at their place of residence, as well as opening a way for drivers from different parts of the country. The easy availability of charging at busy stations can be a game changer for drivers who have always been hesitant to buy an electric vehicle because of concerns that they’ll be unable to discover chargers in clear, lighted and secure locations when needed.

According to the estimates by the White House, there are already more than 3 million electric vehicles being served by 130,000 chargers spread out throughout the nation. A charging network supported by Walmart will dramatically increase this and allay concerns about restricted charger accessibility because, according to Walmart, 10 miles or less separate 90% of Americans from a Walmart store.

According to Walmart’s mission, the organization wants to charge a lower price daily that will help ease the costs of transportation, which continue to be the most expensive household expense in many parts of the nation. More importantly, members and consumers will be comfortable buying family necessities or having a meal while they’re charging with Walmart’s chargers located at all of its superstores, markets in the neighborhoods, and Sam Clubs.

The increased penetration of Walmart’s network will also aid in increasing the domestic capacity for electric vehicle chargers throughout the United States as more drivers move toward electric vehicles.

The investment in this plan is the latest from Walmart to try and transform its business and chain of supply of goods into a more regenerative one, so that the company can help mitigate emissions and improve customer efficiency. For instance, in order to meet its goal of being emissions free by 2040, Walmart has introduced tests in all fuel and vehicle categories throughout the supply chain. And many customers in its W+ program have been receiving regular deliveries through electric cars since last year.

The different programs being undertaken are helping to change perceptions about EV ownership, just as business at Walmart is also evolving to address the changing needs of customers. Walmart is now recognized for both its daily low prices and its convenience. Making owning an electric vehicle simple and straightforward is just one example of Walmart’s commitment to offering consumers, members, employees, suppliers and society as a whole the services required and desired in a manner that fits their way of life.

As companies such as Walmart are moving to make more charging stations available, other companies such as QuantumScape Corp. (NYSE: QS) are looking to develop better batteries so that a single charge can do so much more without the need for frequent recharging coming up.

QuantumScape Corp. (QS), closed Thursday's trading session at $7.42, off by 6.9009%, on 5,774,411 volume. The average volume for the last 3 months is 71.382M and the stock's 52-week low/high is $5.11/$17.9661.

The QualityStocks Company Corner

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

Glioblastoma is an aggressive brain cancer that invades braintissue. The average life expectancy following diagnosis for thiscancer is 14 to 16 months. Globally, the standard of care for patients with this type ofcancer includes chemotherapy with temozolomide, which extends apatient’s expectancy by about two months. Patients may also undergoradiotherapy as well as surgery to remove tumors.

However, even after rigorous treatment cycles, glioblastoma cells may develop resistance totemozolomide over time, heightening the chances of tumor relapseand decreasing its effectiveness.

Researchers at the University of Toronto and The Hospital for Sick Children may have developed a new way to treat tumor cells for all cancers,including chemo-resistant cancers. In a new study, the researchers presented a novel approach that uses precision magnetic control in a process termed“mechanical nanosurgery” to treat aggressive, chemo-resistantcancers. There is a lot of other research and development beingundertaken by the likes of CNS Pharmaceuticals Inc. (NASDAQ: CNSP) with regard to brain cancer, and there is hope that these effortswill yield novel treatments that will improve the clinical outcomesof patients diagnosed with brain cancer.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Thursday's trading session at $2.62, up 48.0226%, on 71,382,295 volume. The average volume for the last 3 months is 30.767M and the stock's 52-week low/high is $0.6105/$11.94.

Recent News

Aditxt Inc. (NASDAQ: ADTX)

The QualityStocks Daily Newsletter would like to spotlight Aditxt Inc. (NASDAQ: ADTX).

Aditxt (NASDAQ: ADTX), a global innovation company focused on therapeutics andtechnologies that monitor and modulate the immune system, hassigned an asset purchase agreement with Cellvera Ltd. According tothe announcement, the agreement gives Aditxt a 50% ownership in GResponse Aid FZE; the remaining 50% ownership belongs to globallogistics leader Agility Inc. Calling the agreement a “significantstep” for the company, Aditxt officials noted that the agreementallows the company to partner with Agility to address a growingglobal market need for effective antivirals. Specifics of thetransaction include the consideration of (A) $24.5 million,comprised of: (i) the forgiveness of Aditxt’s $14.5 million loan toCellvera, and (ii) $10 million in cash, and (B) future royaltiesfor seven years. The announcement also noted that the shareexchange agreement previously entered in December 2021 betweenCellvera Global Holdings LLC (together with other affiliates andsubsidiaries) and Aditxt and all other related agreements will beterminated. The transaction is subject to approval by Aditxt’sboard of directors, financing of the purchase price, regulatoryapprovals for the transfer of shares, the resolution andsatisfaction of all of Cellvera’s creditors inclusive of thosecreditors who have initiated claims, and securing the rights toadditional third-party IP assets. “We believe this acquisition hasthe potential to help drive Aditxt’s strategic revenue and growth,as we move forward to help address a growing market need for moreeffective antivirals,” said Aditxt cofounder, chair and CEO AmroAlbanna in the press release. “We are excited by the opportunity toplay a key role in the development of Avigan in terms of clinicaland commercial opportunities. We believe that Avigan can play avital role in the treatment of a range of infectious diseases, dueto the broad-spectrum nature of the molecule. Although we have onlyrecently entered into the therapeutics market, our goal is to drivea paradigm shift in the treatment and prevention of infectiousdiseases globally through our newly formed subsidiary Adivir.”

To view the full press release, visit https://ibn.fm/SPlbg

Aditxt Inc. (NASDAQ: ADTX) is a biotech innovation company developing technologies focused on mapping and reprogramming the immune system. Aditxt’s immune mapping technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases, and allergies.

As further discussed below, the company’s first commercial product is an immune mapping technology, AditxtScore™, which is designed to provide a personalized profile of the immune system.

The company’s preclinical immune reprogramming technology, Apoptotic DNA Immunotherapy™ (“ADi™”), aims to retrain the immune system to induce tolerance, with the goal of addressing vast unmet needs in transplanted organ rejection, autoimmune diseases, and allergies. The company is developing specific ADi™ products for psoriasis, type 1 diabetes, and skin grafting.

Headquartered in Richmond, Virginia, Aditxt also operates locations in Silicon Valley and New York.

AditxtScore™

AditxtScore™ is a proprietary platform designed to provide a personalized, comprehensive profile of an individual’s immune system. The underlying technology, licensed from Stanford University through an exclusive worldwide agreement, offers a highly sensitive and accurate method of detecting and quantifying cellular responses, allowing greater specificity, quantification, and amplification of both clinical and commercial opportunities.

The company’s first commercial application of the platform, AditxtScore™ for COVID-19, delivers timely reports on vulnerability and immune status relating to SARS-CoV-2 and its known variants, giving consumers and physicians the data needed to make informed health decisions. Potential future applications will offer early detection of an array of conditions, including diabetes, cardio-metabolic maladies and hormonal imbalances.

Aditxt’s AditxtScore™ immune monitoring center in Richmond, Virginia, is operational and designed to support the anticipated increased demand for AditxtScore™ as well as related products and services. The company is currently scaling its capabilities at this location, with a goal of processing up to 10 million immune system tests/reports annually.

ADi™

ADi™ is Aditxt’s immune reprogramming platform addressing disease-causing immune responses while maintaining the immune system’s ability to combat pathogenic infection. The company is commercializing a nucleic acid-based technology called Apoptotic DNA Immunotherapy™ (ADi™) which utilizes a novel approach that mimics the way our bodies naturally induce tolerance to our own tissues (therapeutically induced immune tolerance). Aditxt believes its ADi™ technology platform can be engineered to address a wide variety of indications.

Aditxt is currently developing ADi™ products for psoriasis, type 1 diabetes and skin grafting.

Currently, immuno-tolerance is achievable through chimerism and cell-based therapy, but there is a clinical need for a more practical and cost-effective approach which:

  • Can be made into a product
  • Does not require additional hospitalization
  • Is simple to produce and ship

Preclinical studies have demonstrated that ADi™ treatment significantly and substantially prolongs graft survival, in addition to successfully “reversing” other established immune-mediated inflammatory processes. ADi™ treatment is not expected to require hospitalization, instead being delivered as an injection in minute amounts into the skin.

IP Portfolio

Both AditxtScore™ and ADi™ are supported by a strong IP portfolio.

AditxtScore™, built upon initial technology invented, licensed from and used at Stanford University, is protected by U.S. patents encompassing methods, systems, and kits for detection and measurement of specific immune responses.

ADi™ technology is protected by seven patent families, including:

  • 8 U.S. patents
  • 4 pending U.S. patent applications
  • 86 foreign patents and 14 pending foreign patent applications spanning the EU, Australia, Canada, Japan, China, India and Hong Kong

These patents are broadly categorized into three groups:

  • Autoimmune diseases and Type 1 Diabetes
  • Organ transplantation and a method of producing plasmid DNA to prevent immune activation
  • Composition of matter for a tolerance delivery system for antigens of interest

Aditxt also possesses and/or in-licenses substantial know-how and trade secrets relating to the development and commercialization of its product candidates, including related manufacturing processes and technologies.

Market Overview

The potential market opportunities presented by immune monitoring and reprogramming are extensive, particularly as Aditxt continues to evaluate additional applications for the platforms.

The company’s initial focus on organ transplantation and related autoimmune response provides some insight into the potential of its approach. According to BCC Research, the global organ and tissue transplantation and alternatives market is on course to reach $120.3 billion by 2024, recording a CAGR of 7.4% from 2019. Industry data suggest that approximately 50% of all transplanted organs are rejected within 10-12 years, further highlighting the critical need for a practical, cost-effective solution to harmful autoimmune responses.

Through its focus on the COVID-19 testing market with AditxtScore™, Aditxt demonstrated the wide-ranging potential of its portfolio. Fortune Business Insights estimated the global COVID-19 diagnostics market at $48.64 billion for 2022. While demand for COVID-19 diagnostics is expected to lessen in the coming years, Aditxt will be uniquely positioned to leverage its existing infrastructure stemming from these operations as the company works to advance broader applications for the AditxtScore™ platform.

Leadership Team

Amro Albanna is the Co-Founder, Chairman, and CEO of Aditxt. He has founded multiple startups to commercialize innovations in various industries, including healthcare, enterprise software, telecommunications, nano technology, consumer health, and biotech. Mr. Albanna has led numerous M&A and going-public transactions as a founder, co-founder, and senior executive.

Shahrokh Shabahang, D.D.S., MS, Ph.D., is the company’s Co-Founder, Chief Innovation Officer, and a member of its board. He brings to the team more than 20 years of experience in developing and commercializing life science technologies focused on product and clinical development in the fields of microbiology and immunology.

Corinne Pankovcin, CPA, MBA, is the President of Aditxt. Prior to joining Aditxt, Ms. Pankovcin served as CFO for several world class organizations, including Business Development Corporation of America, Blackrock Kelso Capital and AIG Capital Partners. In these roles, Ms. Pankovcin was responsible for executing portfolio investments and managing significant M&A transactions.

Thomas Farley is the Chief Financial Officer of Aditxt. From December 2015 to June 2020, Mr. Farley was the Controller and Treasurer of Business Development Corporation of America (“BDCA”), a publicly listed business development company. Prior thereto, from January 2011 to August 2015, Mr. Farley was the Senior Controller of Blackrock Capital Investment Corporation (NASDAQ: BKCC). Prior to joining BlackRock Capital Investment Corporation, Mr. Farley was a Senior Controller for PineBridge Investments Emerging Markets practice. Mr. Farley was also an Accounting Manager for Bessemer Venture Partners prior to his tenue at PineBridge. Mr. Farley began his career with PricewaterhouseCoopers LLP, from 1996 to 2001. Mr. Farley earned his B.S. in Accounting from Long Island University and is a Certified Public Accountant.

Rowena Albanna is the company’s Chief Operating Officer. Ms. Albanna has over two decades of experience in senior leadership roles for both technology startups and public companies. Ms. Albanna’s experience spans a wide variety of industries, including biotechnology, insect control, nanotechnology, consumer electronics, financials, telecommunications, e-commerce, online marketing, medical, and defense.

Matthew Shatzkes is the Chief Legal Officer and General Counsel of Aditxt. As a former partner at an AM Law 50 law firm, Mr. Shatzkes advised a wide variety of healthcare related entities, including biotech companies, on corporate, regulatory, and strategic business matters. Mr. Shatzkes will oversee all aspects of the legal functions at Aditxt, including, providing advice and counsel on governance, regulatory matters, strategic alliances, mergers and acquisitions, and commercial transactions.


Aditxt Inc. (NASDAQ: ADTX), closed Thursday's trading session at $1.01, up 17.4419%, on 30,766,592 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $11.94/$.

Recent News

IGC Pharma Inc. (NYSE American: IGC)

The QualityStocks Daily Newsletter would like to spotlight IGC Pharma Inc. (NYSE American: IGC).

A federal judge has found that it is unlawful to prohibit marijuana users from owning or selling firearms. Paola Connelly, who lives in ElPaso, Texas, was found guilty of distinct offenses for having andmoving a gun in 2021 while accepting that she was a marijuanaconsumer; she was cleared after the United States Federal Court forthe Texas West District agreed to review the case.

A recent decision by the United States Appeals Court for the 5thCircuit forced a re-evaluation after the court had earlier giventhe conviction. The decision centered on an earlier ruling established by the Supreme Court of theUnited States, which held that any constraints on firearms must be in keepingwith the past background of the second amendment’s initialenactment in 1791. Numerous objections to the prohibition of gunsfor cannabis consumers have their roots in the Supreme Court’sdecision. Judge Cardone Kathleen rejected the DOJ’s efforts to drawparallels between the prohibition of cannabis and statutesprohibiting the use of firearms while inebriated and theconsumption of marijuana by those who are regarded as “unvirtuous.”For patients who will have the chance to use marijuana-basedformulations from companies such as IGC Pharma Inc. (NYSE American: IGC) once they gain regulatory approval, no such concerns about gunownership rights will arise since those patients will be using afederally approved medicine.

IGC Pharma Inc. (NYSE American: IGC), through subsidiary IGC Pharma, develops, patents, and markets advanced THC-based drug formulations for the treatment of symptoms related to various diseases including but not limited to Alzheimer’s disease, Tourette syndrome, chronic pain, and pet seizures.

IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia, the first study in humans of a natural tetrahydrocannabinol (THC) compound plus another molecule (www.clinicaltrials.gov). As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC-based formulation on Alzheimer’s patients.

The company’s other drug candidate, TGR-63, is an enzyme inhibitor that has shown in preclinical trials the potential to reduce neurotoxicity in Alzheimer’s cell lines. Both drug candidates have shown their ability to ameliorate beta amyloid plaques in Alzheimer’s cell lines and improve memory in Alzheimer’s mouse models. Beta amyloid plaques are a key hallmark of Alzheimer’s and an important target of Alzheimer’s pharmaceutical drug development.

Neuro Psychiatric Symptoms (NPS) are not only debilitating for Alzheimer’s patients; they also place an immense emotional burden on their caregivers. Beyond reducing symptoms, IGC-AD1’s active molecules and TGR-63 have also shown promise in preclinical trials to reduce important hallmarks of Alzheimer’s including plaques and tangles, as well as improving the treatment of memory loss.

Over the past eight years, the IGC team has amassed a deep knowledge of cannabinoid science, including extraction, isolation, purification, and development. The company’s strategy is to leverage its unique end-to-end capabilities, platform, and expertise to develop a class-leading program and bring it to market quickly and cost efficiently to treat neurodegenerative diseases such as Alzheimer’s.

The company also has a family of cannabidiol (CBD)-based consumer products (www.Holief.com) such as pain relief creams, pain relief gels, purpose gummies, tinctures, and capsules targeting women’s wellness, with a particular focus on premenstrual syndrome (PMS) and dysmenorrhea (period cramps). In addition, the company targets individuals that need sleep-aids with its specially formulated low melatonin cannabinoid gummies.

IGC has also introduced a low-calorie CBD- and caffeine-infused energy beverage brand (www.SundaySeltzer.com) that is currently available for purchase. The company’s brands are founded on the belief that effective natural solutions should be affordable and accessible to everyone. As the demand for natural products targeting women’s wellness and energy drinks continue to grow, these products are seeing strong traction in the market.

The company operates three facilities – a large GMP (Good Manufacturing Production Standards) certified facility that includes extraction, distillation, and manufacturing, in Washington State; a GMP-211 (pharmaceutical) grade facility in Maryland; and a facility licensed for controlled substances including cannabis in Bogota, Colombia, with complete access to legal licensed cannabis where the company conducts its testing.

In addition, the company’s development under Magistral Formulations is approved by INVIMA (Colombia National Food and Drug Surveillance Institute) to treat neurological disorders, non-oncological chronic pain, and mental disorders.

IGC’s intellectual property (IP) portfolio comprises of eight patents that it controls and seven patent applications. The portfolio includes #11,446,276, a patent for extreme low dose THC treatment of Alzheimer’s that was granted in September 2022.

The company is headquartered in Potomac, Maryland.

IGC-AD1

IGC-AD1 is the company’s leading drug candidate for the treatment and relief of Alzheimer’s symptoms. A significant amount of research on Alzheimer’s cell lines has shown that the active agents in IGC-AD1 reduce plaques and neurofibrillary tangles that are the hallmarks of Alzheimer’s. Further, micro-dosing of THC, as shown in cell lines, could increase the functioning of mitochondria and potentially promote the growth of new neural pathways (neurogenesis). The research shows that micro-dosing of THC affects the brain radically differently from the normal higher dosing of THC.

While there is a significant body of research showing that THC is neuro-toxic at normal levels of dosing, micro-dosing of THC has been shown to be non-toxic to neurons. With the results of these preclinical studies, the company developed an oral formulation, IGC-AD1. The company recently completed a safety and tolerability Phase 1 trial on Alzheimer’s patients and has initiated a Phase 2, multi-site, double-blind, randomized, placebo-controlled trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimer’s disease at sites in the U.S. and Canada. IGC expects the Phase 2 trial to take between 9 and 12 months to complete, barring unknown factors such as, for example, a resurgence of COVID and the enforcement of lockdowns and travel restrictions.

With further successful trials and FDA approvals, IGC hopes to bring a drug based on natural THC as an effective treatment for agitation in Alzheimer’s to market.

TGR-63

The company’s other molecule, TGR-63, has been shown to reduce the neurotoxicity that impacts memory loss in preclinical trials with mice. On a dose dependent manner, transgenic Alzheimer’s mice treated with TGR-63 showed improvement in memory relative to control.

Both drug candidates, IGC-AD1 and TGR-63, have shown their ability to reduce the brain plaques associated with memory loss in Alzheimer’s in mice.

With further successful trials and FDA approvals, IGC hopes to bring TGR-63 as a treatment for Alzheimer’s disease to market.

Market Opportunity

Alzheimer’s disease impacts over 55 million people worldwide and about 5.5 million individuals in the U.S. Over 70% of these patients face debilitating symptoms, including anxiety, depression, and agitation (Mendez, 2021). Agitation in dementia patients can include excessive physical movement and verbal activity, restlessness, pacing, belligerence, aggression, screaming, crying, and wandering.

In 2020, the estimated healthcare costs for Alzheimer’s disease in the U.S. were $305 billion. Medicare and Medicaid covered about 70% of those costs, leaving considerable burden on patients and families. At the current rate of growth of Alzheimer’s and other dementia diagnoses, those costs are estimated to reach over $1 trillion by 2050.

Currently, there are no FDA-approved medications to alleviate the symptoms of dementia due to Alzheimer’s disease, providing a tremendous opportunity for formulations that can have an impact on quality of life and disease progression.

Management Team

Richard Prins has been chairman at IGC since 2012 and served as an independent director since 2007. From March 1996 to 2008, he was the Director of Investment Banking at Ferris, Baker Watts, Incorporated. Prins served in a consulting role to RBC until January 2009. He currently volunteers full time with a non-profit organization, Advancing Native Missions, and is a private investor. Since February 2003, he has been on the board of Amphastar Pharmaceuticals Inc. He holds a bachelor’s degree from Colgate University and an MBA from Oral Roberts University.

Ram Mukunda is CEO and President of IGC. He has been the chief inventor and architect of most of the company’s patent filings and is responsible for the company’s strategic positioning. Prior to IGC, he was founder and CEO of Startec Global Communications, which he took public in 1997. He served as Strategic Planning Advisor at Intelsat, a communications satellite services provider. From 2001 to 2003, he was a Council Member at Harvard’s Kennedy School of Government, Belfer Center of Science and International Affairs. He was named the 1998 Ernst & Young Entrepreneur of the Year. He holds bachelor’s degrees in electrical engineering and mathematics, and a master’s degree in engineering from the University of Maryland.

Dr. Jagadeesh Rao is the company’s Principal Scientist. His career spans two decades in the public sector and product R&D for Johnson & Johnson. He leads IGC’s scientists in the development of pharmaceutical and OTC products. He worked for the federal National Institutes of Health, and for the National Institute on Drug Abuse. His Ph.D. in Neurochemistry is from the National Institute of Mental Health & Neurosciences in India. He did postdoctoral training at the University of Illinois-Chicago.

Claudia Grimaldi is a Director, Vice President, Principal Financial Officer, and Chief Compliance Officer for IGC. She also serves as a Director/Manager Director for some of the company’s subsidiaries. She graduated with highest honors from Javeriana University in Colombia with a bachelor’s degree in psychology. She holds an MBA, graduating with highest honors, from Meredith College in North Carolina. In addition, she has attended the Darden School of Business Financial Management Executives program and the Corporate Governance Program at Columbia Business School. She is currently pursuing her Directorship Certification with the National Association of Corporate Directors. She is fluent in both English and Spanish.

IGC Pharma Inc. (NYSE American: IGC), closed Thursday's trading session at $0.3705, up 4.661%, on 61,239 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.2785/$0.8505.

Recent News

Battery Mineral Resources Corp. (TSX.V: BMR) (OTCQB: BTRMF)

The QualityStocks Daily Newsletter would like to spotlight Ucore Rare Metals Inc. (TSX.V: BMR) (OTCQB: BTRMF).

BRM completes “mutually beneficial agreements” with two Chileancommunities

Company committed to develop productive, ethical and transparentrelationships with surrounding neighborhoods

BRM also finalizes comprehensive policy, strategy andimplementation guide

In its ongoing commitment to ESG as well as supporting andpartnering with the communities where it operates, Battery Mineral Resources (TSX.V: BMR) (OTCQB: BTRMF) has been announcing key community and social initiatives at itsChile-based Punitaqui Project (https://ibn.fm/Rexrs). Specifically, the company has completed agreements with thePotrerillos Community (Comunidad Agricola Potrerillos) and thePunitaqui Community (Comunidad Agricola Punitaqui).

Battery Mineral Resources Corp. (TSX.V: BMR) (OTCQB: BTRMF) is a battery minerals company providing shareholders exposure to the global mega-trend of electrification while being focused on growth through cash-flow, exploration and acquisitions in favorable mining jurisdictions.

The company’s mission is the discovery, acquisition and development of battery metals (namely copper, cobalt, lithium, and graphite) in North America, South America and South Korea. It aims to become a leading low-cost producer of high quality, ethically sourced battery metals from high-grade, low impact mines in stable jurisdictions that are close to major consumer industries.

BMR is headquartered in Vancouver, British Colombia, with a portfolio of projects spanning Canada, the U.S., Chile and South Korea.

Project Portfolio

BMR’s current focus is the restart of its Punitaqui copper mine in Chile, as well as the exploration and development of its cobalt, lithium and graphite assets in North America and South Korea. The company also continues to identify and evaluate new project opportunities in its operating jurisdictions.

Its current portfolio includes:

Chile – Copper

BMR’s 100%-owned Punitaqui copper mine, acquired in March 2021, has the potential to generate an annual EBITDA of up to $50 million at or above a copper price of $4.25/lb. The company’s flagship project, the Punitaqui mine has been the subject of numerous milestones in recent months, including:

  • BMR funded and completed a successful 32,526m resource drill program in 2022. Metallurgical testwork has confirmed the ability to produce excellent copper concentrates from each of the five zones tested, including recoveries ranging from 81% on the low end at Cinabrio Norte up to 96.5% at the Dalmacia deposit.
  • The company in August 2022 reported the results of its first ever NI 43-101-compliant resource estimate for the underground deposits at its Punitaqui copper mining complex of 6.2 million tonnes grading 1.14% Cu in indicated category, along with 3.1 million tonnes grading 0.93% Cu in the inferred category. This resource estimate greatly exceeded management goals.
  • In September 2022, BMR announced the approval by the Chilean Environment Assessment Service for the Environmental Impact Declaration (“DIA”) pertaining to mining at the company’s Cinabrio mine and San Andres deposit. The approval of the DIA allows BMR to move forward with starting mining operations in 2023 and restarting the mill at its Punitaqui copper mining complex soon after.
  • BMR is focused on securing the final funding for the restart of mining and resumption of copper concentrate production at Punitaqui. Once this funding is received, BMR aims to complete mine rehabilitation and development in four to six months, with the ramp up from first production to the full production rate of 20-25 million pounds of copper in concentrate per annum to require a further four to six months.

“From exploration, engineering, community and permitting successes to realizing several non-dilutive means of funding to allow BMR to advance the project, our team looks forward to taking advantage of the renewed positive market sentiment for near term copper pricing and placing ourselves in a strong position to participate in a robust copper sector in 2023,” CEO Martin Kostuik stated in a news release.

Canada – Cobalt/Silver

Between 2016 and April 2018, BMR acquired through claim staking, option, joint venture and direct purchase the largest regional land holding in the historic home of high-grade cobalt-silver veins in Canada known locally as the Cobalt Embayment.

As of February 2023, BMR controlled a land package totaling 9 properties with 4,086 tenements that encompass an area of 84,003.39Ha. The key projects within the land package include McAra, Gowganda, Elk Lake, Fabre and Wilder. From 2017-2022, a total of 412 holes/51,452.34m were drilled on eight projects/20 targets. In addition, a total of 26,709 Line-Km of airborne geophysical surveys & 1,324.84sqkm of LiDAR topography was flown. Follow-up ground geophysical surveys resulted in a total of 37 surveys (514.64 Line-Km) being completed.

Initial NI 43-101 compliant resource defined at McAra (M&I Resource of 1,124,000lbs Co) was detailed in a Technical Report on Cobalt Exploration Assets in Canada dated as of February 5, 2021, with an effective date of October 31, 2020, prepared by SRK Consulting – G Cole PGeo (APGO#1416).

Idaho – Cobalt

BMR holds the Bonanza and East Fork properties located in the historic cobalt-copper-gold Blackbird mining district (Blackbird Mine from 1902-1963 produced 17Mt grading 0.7% Co, 1.4% Cu, and 1 g/t Au) located about 30 kilometers west of Salmon, Idaho. The Bonanza project is immediately adjacent to Jervois Global’s Idaho Cobalt Operations, the United States’ only operating primary cobalt mine. At Bonanza, there are seven mineralized sites within an area over three kilometers wide that extends along a gabbro dyke striking continuously for over six kilometers northward from Noranda’s historic Blackbird Cobalt/Copper mine. The showings on the project are Bonanza Copper Tunnels, Tinker’s Pride, Bonanza Copper #25, Indian Creek, Gray Copper, Blackrock #4 and Papoose #’s 1-4.

From 2018-2021, BMR’s Bonanza Exploration included 550 line-km of airborne magnetics and radiometrics followed up by surface exploration that included rock sampling, soil sampling, channel sampling of historic workings and 3.6km of time domain induced polarization geophysics.

The two properties cover 12 significant cobalt-copper prospects within the known mineralized zone. Both of the BMR Idaho cobalt belt properties host excellent high-grade discovery potential.

South Korea – Graphite

BMR has 100% ownership of the Guemam and Taehwa graphite exploration projects containing high-purity flake graphite deposits. Both assets are past-producing mines with existing local infrastructure and near-term production potential.

Nevada – Lithium

The company’s Amargosa lithium project is in the southern Basin & Range province and central Mojave Desert of Nevada. It is an early-stage exploration opportunity in a favorable region that hosts numerous lithium occurrences, including the Clayton Valley lithium deposit owned by Cypress Development Corp., as well as a major nearby lithium brine mine currently in production called the Silver Peak mine held by Albermarle Corp., one of the world’s largest lithium producers.

Market Opportunity

Near-term forecasts for the copper sector are extremely bullish, with stalwart Wall Street firms such as Goldman Sachs and Bank of America projecting record highs in the coming months. A combination of short-term supply deficits and long-term energy transition demand are expected to buck the downward pressures that have impacted copper prices in recent years.

Goldman in December 2022 forecast a 178K metric ton deficit in the copper market in 2023, causing the firm to raise its 12-month target to $11K/ton and its average price for calendar 2023 to $9,750/ton.

With China likely to continue accelerating efforts to restock depleted inventories in the wake of its COVID-19 reopening and a sustained push toward electrification around the globe placing a strain on supply, BMR is uniquely positioned to capitalize through the anticipated restart of operations at its Punitaqui copper mine.

Management Team

JMartin Kostuik is CEO and a Director of BMR. He brings to the company nearly three decades of diversified experience in the mining industry as a mining engineer and senior executive. Prior to joining BMR, Mr. Kostuik served as president and director of Arizona Gold Corporation and as CEO and director of Rupert Resources Limited. He built a broad base of experience in operations, engineering, exploration and capital projects with various companies including Luna Gold (Equinox), Barrick Gold Corporation, Taseko Mines Limited and DMC Mining Services. Mr. Kostuik earned his B.S. in Mining Engineering from Queen’s University and his M.B.A. from the University of Tennessee.

JMax Satel is the company’s CFO. He has over 18 years of experience as a successful natural resources-focused executive, most recently serving as EVP Corporate Development & Investor Relations for Arrow Exploration Corp., a TSX Venture- and AIM-listed oil & gas company with operations in Colombia and Canada. Prior to joining Arrow, Mr. Satel was principal and co-founder of Bordeaux Capital Inc., a Toronto-based advisory firm focused on the capital needs of companies across the natural resources sector, where he led and executed project financing advisory mandates involving global financial institutions and private equity funds. He earned a Bachelor of Commerce in Finance and Economics from the University of Toronto.

Jacob Willoughby is VP Corporate Development & Strategy for BMR. He brings to the company nearly 17 years of diversified experience in mining capital markets, including over eight years as a mining analyst covering exploration and development companies globally in both precious and base metals. Mr. Willoughby was most recently Vice President of Research and Analyst at Red Cloud Securities in Toronto. He spent two years as President and Director of Aldridge Minerals, a former Canadian based public exploration and development company with assets in Turkey and Papua New Guinea. Mr. Willoughby earned both a B.S. in Geology and a Masters in Business Administration from the University of Windsor.

FingerMotion Inc. (BTRMF), closed Thursday's trading session at $0.16, up 7.8894%, on 6,000 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0355/$1.05.

Recent News

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF)

The QualityStocks Daily Newsletter would like to spotlight Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF).

As the prevalence of mental health conditions increases, so does interest in new treatments for these disorders. One particular area of interest ispsychedelic-assisted psychotherapy, which involves the supervisedadministration of psychedelic drugs, such as psilocybin andketamine, in conjunction with therapy.Psychedelics have been used for centuries by Indigenous communities for their spiritual and religious ceremonies. These substances areknown to alter an individual’s mood and perception as well as theircognitive processes. This means these treatments possess thepotential to make cognitive behavioral therapy and other talktherapies more effective.Given these effects, patients are bound to be more vulnerable whileunder the influence of psychedelics, which highlights the need forprocesses and systems that would ensure patient safety. This is whyHealth Canada issued a notice in December 2022 on risk-managementof psychedelic-assisted psychotherapy for therapists, informedconsent and clinical settings. The prospect of having accreditationstandards for this rapidly growing industry is something that majoractors such as Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are likely to welcome because it would smoot out severaloperational matters, including how to better screen potentialemployees.

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and Ketamine Infusion Centers, one of the largest ketamine clinics in the country.

Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses. Its founders helped build the multi-billion-dollar cannabis industry and aim to do the same in psychedelics as it follows a similar path toward legalization. In its quest to advance the new psychedelic renaissance upon us, Delic has become the pioneer in its field, creating an ecosystem of opportunities by investing in cutting-edge ideas.

The Vancouver-based company was formed in 2019 to address the growing interest in psychedelic wellness backed by science. Delic was the ‎first psychedelic umbrella platform. It is currently a trusted source for those interested in ‎psychedelic culture, education, treatments, and more.

While other emerging companies focus on patent medicine and big pharma for substances limited by government regulation, Delic is blazing a unique trail. It identifies ancillary and fully legal opportunities like IP, new media, live events, ketamine clinics (with the ability to offer additional psychedelic treatments once legalized, and large-scale production and brings them under its big tent of resources and reach.

The Big Problems Delic Is Addressing

  • Fifty percent of Americans will meet the criteria for a mental health condition sometime in their lifetime. The FDA has approved psilocybin therapy as a breakthrough therapy for depression.
  • Every 40 seconds, someone in the world commits suicide. Ketamine has been shown to decrease thoughts of suicide significantly. In 2019, the FDA approved esketamine as a fast-acting antidepressant.
  • Traditional palliative care methods do not eradicate end-of-life (EOL) anxiety. LSD and psilocybin have been shown to reduce EOL anxiety for terminally ill patients. Eighty percent of terminally ill patients with psilocybin sessions experienced significant reductions in depression and anxiety.
  • Approximately 50 million people in the U.S. are addicted to some tobacco product. Research shows that psilocybin is helping people quit smoking.

The Delic Ecosystem

The Delic Ecosystem covers three main areas: media, health, and science. The media focus is educating and motivating the masses through a variety of digital platforms, like Delic’s Reality Sandwich digital magazine, a free public education platform providing psychedelic guides, news and ‎culture (1.4+ million page views in 2020 and 54k social media followers across all platforms); Meet Delic, the first-ever psychedelic wellness summit and the premier psychedelic wellness event based in Las Vegas (over 2,000 live attendees and 5,000+ email subscribers); and Delic Radio (over 43 episodes and 100k total streams). Delic has also been featured in numerous media outlets like Forbes, NBC News, The Joe Rogan Experience, Daily Beast, High Times, and The Dr. Drew Podcast.

The focus of Delic’s health operations is the most accessible psychedelic treatments that can help billions of people live happier lives. Delic does this through one of the largest ketamine clinic chains in the country, Ketamine Infusion Centers (KICs), a limited liability corporation formed under the laws of Arizona that runs three ketamine clinics located in Bakersfield, California, and Phoenix, Arizona. Its management team has over 15 years of experience in the clinic and medical space, scaling and operating over 20 clinics, with a plan to open 10 more clinics in the next 18 months. Together, these clinics have overseen 4,000+ treatments delivered to date.

The focus of Delic’s science operations is developing IP and advanced extraction and testing facilities that are the backbone of the legal market. Delic carries this out through Delic Labs, a licensed cannabis and psilocybin research laboratory based in Vancouver. It’s the only entity licensed by Health Canada to exclusively focus on research and development of psilocybin vaporization technology.

Founded by award-winning chemists, Delic Labs focuses on extraction optimization, analytical testing, and chemical process development to advance the cannabis and psilocybin industries. Health Canada gave it a Section 56 Exemption to work with psilocybin compounds, allowing the company to possess and research these products for development and quality control before they hit the market.

Latest Acquisition – Homestead Book Company

On March 4, 2021, Delic announced its acquisition of Seattle-based Homestead Book Company. Homestead is a legacy counterculture distributor of psychedelic media. It’s also the creator of one of the first self-contained psilocybin mushroom grow kits.

The acquisition of Homestead is an exciting one, as it shows how Delic is increasing accessibility to this nascent industry within regulated jurisdictions. Homestead has sold tens of thousands of mushroom kits globally and was one of the earliest distributors for High Times and many other counterculture publications.

The Homestead acquisition allows Delic to increase its product offerings on its website, Reality Sandwich, which recently hit a record for average monthly traffic of over 200,000 unique visitors and over 2.6 million active readers in 2020.

Market Outlook

The psychedelic renaissance is here. Just in time to help address the global mental health crises, plant medicines have the potential to help billions of people live happier lives. Thanks to university-led and FDA-approved studies, North America is leading the way in advancing an industry as psychedelics are becoming accepted globally for therapeutic, medical, and recreational use. Here are some statistics:

  • 32 million people in the U.S. have used psychedelics at least once
  • 17% of all American adults between 21 and 64 have used psychedelics at least once
  • $500 billion is spent in the U.S. every year on prescription drugs
  • $238 billion is spent in the U.S. every year on mental health treatments and ancillary services
  • The anxiety disorder and depression treatment market is estimated at $16 billion
  • $187.8 billion was spent in 2013 on mental health and substance abuse disorders

Management Team

Delic Co-Founder and CCO Jackee Stang was an executive at High Times, a leading counterculture publication that became the voice for the cannabis industry. The monthly magazine had a circulation of over 500,000 copies per issue. Its website attracted 500,000 to five million users each month by 2014.

Likewise, company Co-Founder and CEO Matt Stang was a previous owner and operator of High Times, a position from which he played an instrumental in legalizing cannabis in multiple states and launched the Cannabis Cup in America. After interacting with the cannabis community for two decades, he helped found Delic in 2019 as one of the first psychedelic corporations. He shapes the company’s vision and path using his expertise in branding, marketing, business development, and product viability.

Delic’s VP of Business Development, John Coleman, Ph.D., is a former president of Anandia Labs, a biotech company focused on genetics and analytics. Having experience in both science and business, Dr. Coleman is well-equipped to lead Delic’s business development efforts as it strives to enter new vertical markets.

Zak Garcia is the company’s Chief Marketing Officer. He was the former CMO of Bulletproof Inc., maker of the well-known Bulletproof Coffee brand. Mr. Garcia is a marketing and leadership strategist who helped grow Bulletproof Coffee to over $250 million in revenue.

Delic Holdings Corp. (DELCF), closed Thursday's trading session at $0.007, up 2.9412%, on 1,073 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0031/$0.092105.

Recent News

Fintech Ecosystem Development Corp. (NASDAQ: FEXD)

The QualityStocks Daily Newsletter would like to spotlight Progressive Care Inc. (OTCQB: FEXD).

Fintech Ecosystem Development Corp. (NASDAQ: FEXD) is a special purpose acquisition company (“SPAC”) formed to effectone or more business combinations with an intent to focus on thefinancial technology sector. The FEXD management team has extensiveexperience in developing global fintech platforms and services.“The company’s mission is to create and grow a global financialecosystem to address unmet mobile money needs in developing andindustrialized countries and markets. FEXD plans to achieve this byacquiring and merging with financial technology pioneers that havethe potential to help establish its global fintech ecosystem and bycontinuing the development of proprietary technologies andapplications to keep the company at the forefront of the cashlesssociety market. Digital money is replacing physical cash… FEXD isdeveloping mobile transaction platforms, applications and servicesthat are helping to implement these changes,” a recent articlereads. “The company plans to offer a diverse portfolio of productsand services to consumers and businesses in the United States,South Asia, East Asia, Africa, Europe, and Latin America. Itsgrowth strategy includes acquisition, innovation and marketdevelopment.”

To view the full article, visit https://ibn.fm/LzuTg

Fintech Ecosystem Development Corp. (NASDAQ: FEXD) is a special purpose acquisition company (SPAC) formed for the purpose of effecting one or more business combinations with an intent to focus on the financial technology sector.

The company’s mission is to create and grow a global financial services ecosystem to address unmet mobile money needs in developing and industrialized countries and markets. FEXD plans to achieve this by acquiring and merging with financial technology pioneers that have the potential to help establish its global fintech ecosystem, and by continuing the development of proprietary technologies and applications to keep the company at the forefront of the cashless society market.

Digital money is replacing physical cash. Consumers can buy products and services from anywhere in the world and make payments across borders. Parents can send money to students studying in other countries. Migrant workers are sending money to families in developing nations. Rural villagers without banks can send and receive money using their smartphones. FEXD is developing mobile transaction platforms, applications and services that are helping to implement these changes.

The company plans to offer a diverse portfolio of products and services to consumers and businesses in the United States, South Asia, East Asia, Africa, Europe and Latin America. Its growth strategy includes acquisition, innovation and market development.

FEXD is a Delaware corporation based in Collegeville, Pennsylvania. The company was launched in May 2021 by a management team led by Dr. Saiful Khandaker that has extensive experience in developing and managing financial service platforms and applications, primarily in the mobile money sector. FEXD is sponsored by Revofast LLC.

Acquisition Targets

In September 2022, FEXD announced definitive agreements for business combinations with Rana Financial Inc., a Georgia corporation, and Mobitech International LLC (dba Afinoz), a limited liability company organized in the United Arab Emirates. The agreements call for Rana and Afinoz to become wholly owned subsidiaries of FEXD, with the combined company expected to continue trading on the Nasdaq under existing ticker symbol ‘FEXD’. The mergers are expected to close in Q2 2023.

Rana Financial

Rana Financial is a licensed money transfer company founded in 2009. Rana provides fast and affordable online and mobile transfer of funds between the U.S. and Latin America. Rana has been providing money transfer services in the U.S. market for 13 years and has 30,000 active users. Rana’s money transfer business grew to 200,000 transactions in 2021. The merger agreement values Rana at an implied $78 million enterprise value.

Mobitech International LLC

Mobitech International LLC (dba Afinoz) is an artificial intelligence-enabled digital lending platform used by India’s leading banks, non-banking financial companies and fintech loan providers. Afinoz’s fintech platform supports enterprises making loans primarily to middle- and working-class borrowers via its website or through its mobile phone application. Afinoz’s platform makes loans available and affordable to millions of Indian workers and unbanked users by providing access at a low cost. Afinoz’s platform has more than 50 lending partners, and its database of registered users in India includes more than two million individuals. The merger agreement values Afinoz at an implied $120 million enterprise value.

Market Opportunity

According to analysis by global market research firm Mordor Intelligence, the worldwide financial technology market is valued at approximately $194 billion in 2023 and is projected to grow to nearly $500 billion by 2028, representing a CAGR of 18.97% for the forecast period. According to the report, various financial crises and the COVID-19 pandemic have fueled consumer adoption of, and investor interest in, fintech over the past several years.

Management Team

Dr. Saiful Khandaker is Founder, CEO and President of FEXD. He is Group CEO and founder of FAMA Holdings Inc., a global developer of fintech platforms, applications and services based in the U.S. with offices in the U.K., India, Bangladesh and Zambia. He is currently leading the development of the FAMACASH™ network, a global fintech ecosystem to provide fast, affordable mobile money services in underserved countries such as Bangladesh. Before founding FAMA, Dr. Khandaker spent more than two decades leading the development of software solutions for Fortune 100 companies and startups. He also helped numerous clients modernize their fintech services as Chief Technology Officer at Mi3. He holds a Doctor of Management in Organizational Leadership, a Master of Science in Technology Management, and a Bachelor of Science in Computer Information Systems.

Jenny Junkeer is CFO at FEXD. She is a Chartered Accountant with over 17 years of experience. As CEO of Junkeer New Era Consulting, she leads a team specializing in helping companies launch and optimize business operations in fast-changing industries. She has extensive experience helping organizations scale operations to maximize value. She is an Adjunct Association Professor at Deakin University in Australia, a board member of the Global Health Initiative Foundation, and Director of Implementation at ConnectCV. She holds a Bachelor of Commerce Degree (Honors) from Monash University.

FingerMotion Inc. (FEXD), closed Thursday's trading session at $10.5, even for the day, on 32 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $9.96/$11.00.

Recent News

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF)

The QualityStocks Daily Newsletter would like to spotlight EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF).

EverGen (TSX.V: EVGN) (OTCQX: EVGIF), a leading Canadian renewable energy company and Canada’srenewable natural gas (“RNG”) infrastructure platform, acquires,develops, builds, owns, and operates a portfolio of RNG,waste-to-energy and related infrastructure projects.“Waste-to-energy technologies, such as those of EverGen, are in usetoday, reducing dependence on finite fossil fuels and puttingwould-be trash to good use in a green manner,” a recent articlereads. “RNG is a carbon-neutral fuel that can be produced frommultiple organic feedstocks, including food and animal waste andwastewater, that is processed in an anaerobic digester intoproducts such as fertilizer and soil amendments or biogas that isfurther refined to be an essentially identical replacement forconventional natural gas. EverGen designs and builds the system andfacilities, collecting organic feedstock from its partners, such asmunicipalities and farms. The RNG output can be used locally orsold to utilities. For instance, EverGen has several agreementswith FortisBC – where the RNG is fed into the existing natural gaspipeline. At its Sea to Sky Soils facility in British Columbia,EverGen keeps organic waste out of landfills by turning it intohigh-quality soil amendments and blends for use on farms, gardensand landscapes.”

To view the full article, visit https://ibn.fm/lbNNt

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF) is developing Canada’s Renewable Natural Gas Infrastructure Platform, starting on the west coast in British Columbia. The company is combating climate change and helping communities contribute to a sustainable future by acquiring, developing, building, owning and operating a portfolio of renewable natural gas (RNG), waste-to-energy, and related infrastructure projects.

While EverGen is currently focused on British Columbia, its continued growth is expected across other regions of North America. RNG is produced differently than conventional natural gas, without drilling wells. RNG is derived from biogas, which is captured from decomposing organic waste in landfills, food waste, agricultural waste matter and wastewater from treatment facilities. This waste feedstock is supplied to an anaerobic digester which contains bacteria that breaks down organic matter in the absence of oxygen. The resulting biogas is captured and cleaned to create carbon neutral or carbon negative RNG to be used by the existing North American gas pipeline grid. By capturing these emissions and transforming them into RNG, then combusting into CO2, the overall greenhouse gases (GHG) impact is materially less potent than allowing natural decomposition to release methane into the atmosphere. Liquid and solid digestate matter is a byproduct of the RNG production process and is used as fertilizer and in other applications.

EverGen operates three projects in British Columbia. The company was incorporated in 2020 and went public in 2021, with its common shares listed on the TSX Venture Exchange under ticker symbol ‘EVGN’. In February 2022, EverGen’s common shares began trading on the OTCQB Venture Market in the U.S. under ticker symbol ‘EVGIF’. The company is headquartered in Vancouver.

Portfolio Projects

Fraser Valley Biogas is one of three projects in EverGen’s portfolio. Located in Abbotsford, British Columbia, the facility has been digesting manure and off-farm organics since 2011 and was the first agricultural digester in Canada to produce RNG. The RNG generated through this project is part of a FortisBC program to supply renewable gas to homes, businesses and other customers. Fraser Valley Biogas also provides Abbotsford farms with renewable fertilizer via the digestate produced. EverGen acquired Fraser Valley Biogas early in 2021 and is currently enhancing and expanding the facility. These optimization projects resulted in record production during the month of September 2021, supporting the growing demand for RNG in British Columbia. Optimization activities contributed an additional 18% of RNG production for September and a 9% higher year-to-date production compared to the previous year. The facility produces approximately 80,000 gigajoules of RNG, enough to heat more than 1,000 homes for a year.

Net Zero Waste Abbotsford, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and RNG expansion project. The British Columbia Utilities Commission recently approved a 20-year offtake agreement between the facility and FortisBC, an electricity and gas utility. Under this agreement, FortisBC will purchase up to 173,000 gigajoules of RNG annually for injection into its natural gas system upon completion of an anaerobic digester project at Net Zero Waste Abbotsford. Once construction is complete, this project is expected to produce enough energy to meet the needs of more than 1,900 homes.

Sea to Sky Soils, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and potential future RNG expansion project which has been operating near Pemberton, British Columbia, on Lil’wat Nation land since 2012. The Lil’wat Nation is a key partner and supporter of the facility, which has employed a majority of its staff from the First Nation since inception. The Sea to Sky Soils facility processed approximately 160 percent of its forecast tonnage in the second half of 2021. In total, Sea to Sky Soils processed approximately 36,000 tons of organic waste in 2021. The facility is working with the Ministry of Environment to expand its operational capacity in 2022. EverGen has partnered with local municipalities – including Metro Vancouver and the municipality of Pemberton – for the delivery of additional organic waste to the facility. The facility is an important part of EverGen’s RNG infrastructure platform and serves as a source of valuable feedstock to support the company’s existing and future operations.

Market Outlook

A report from Global Market Insights states that the biogas market is projected to see significant growth over the next few years, driven by a shifting preference to utilize biogas to reduce emission levels from traditional fuels. Escalating RNG usage by gas utilities as a sustainable and low carbon alternative to supply heat and electricity in industries and buildings will further stimulate growth. RNG is increasingly deployed across the transport sector, especially for heavy vehicles and vessels, to abate GHG emissions.

Many North American gas utilities have set RNG targets of 5% to 15% of production by volume in 2030, compared to less than 1% by volume in 2020. FortisBC has a goal of including 15% RNG in its gas supply by 2030. EverGen believes this presents a potential C$16 billion+ opportunity for RNG producers.

Management Team

Chase Edgelow is co-founder and CEO at EverGen. He has over 15 years of specialized private investment, finance, and technical expertise in the energy and infrastructure sectors. His background is as a Facilities Engineer with Petro-Canada, independently managing energy infrastructure capital projects located in western Canada. He holds a Professional Engineer designation from the province of Alberta.

Mischa Zajtmann is co-founder and President at Evergen. He has 15 years of experience providing consulting and management for Canadian and American companies in the natural resources and energy space. He is a corporate securities lawyer who began his career at Blake, Cassels & Graydon LLP. His J.D. is from the University of Saskatchewan Law School. He’s a member of the British Columbia Bar.

Sean Mezei is COO at EverGen. He has 20 years of experience in the RNG industry, having served previously as the president of Greenlane Biogas and as a senior manager at QuestAir, and founder and president of Dekany Consulting. He was a co-chairman of the American Biogas Council’s RNG working group for six years. He has been a Registered Professional Engineer in the province of British Columbia since 1994.

Natasha Monk is CFO at EverGen. She is a CPA with 12 years accounting, financial reporting, and tax experience in public practice and industry. She is currently a partner at Affirm LLP, where she advises and consults to a wide variety of companies in multiple industries across public and private sectors. Prior to joining EverGen, she worked at KPMG. She graduated from the University of Calgary.

EverGen Infrastructure Corp. (OTCQX: EVGIF), closed Thursday's trading session at $2.47, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $1.365/$3.20.

Recent News

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)

The QualityStocks Daily Newsletter would like to spotlight Energy Fuels Inc. (UUUU).

More and more countries are working to adopt greener energy sources and reduce their greenhouse gas emissions. Turning to solar andwind energy to meet demand will not only reduce the use of coal but also help countries meet the targets set in the 2015 ParisAgreement.The Paris Agreement establishes an international framework to steer clear ofcatastrophic climate change by keeping global warming below 2o C and trying to reach a 1.5o C limit. Earlier this week, Germany closed its remaining atomicpower stations amid conflict between two groups: politicians andconservative commentators on one side with greens and left wingerson the other. Given the current energy crunch in different parts ofthe world resulting from the war in Ukraine, the uranium extractedby miners such as Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) provides a way to address the energy deficits, so it isunderstandable that a significant section of the German populationis outraged that the country decommissioned its remaining nuclearenergy plants.

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR),based in Lakewood, Colorado, is the country’s largest producer of uranium and the leading conventional producer of vanadium, both designated by the U.S. government as critical minerals.

As the leading U.S. diversified uranium miner, Energy Fuels’ uranium production portfolio stands apart in the world. Energy Fuels has more uranium production facilities, more production capacity, and more in-ground resources than any other company in the United States. In fact, the company’s assets have produced over one-third of all U.S. uranium over the past 15 years and is uniquely positioned to increase production to meet new demand.

Energy Fuels utilizes both conventional and in-situ recovery (“ISR”) technology to produce uranium from three strategic facilities:

  • White Mesa Mill in Utah (conventional) has a licensed capacity of over 8 million pounds of U3O8 per year. The highly strategic White Mesa Mill is the only conventional uranium mill in the country and is proximate to some of the largest and highest-grade uranium mines and projects in the U.S., including the Company’s Canyon mine, La Sal Complex, Henry Mountains Complex and Roca Honda Project. White Mesa Mill provides Energy Fuels with significant production scalability as uranium demand increases. The White Mesa Mill also has other diverse businesses, including vanadium, rare earth elements (REE’s), alternate feed materials recycling and land cleanup, all described below.
  • Nichols Ranch Plant (ISR) is located in the productive Powder River Basin district of Wyoming and has a total licensed capacity of 2 million pounds of U3O8 per year. Nichols Ranch has produced 1.2 million pounds of U3O8 since commissioning in 2014, and it has significant future expansion potential from 34 fully licensed wellfields containing significant in-ground uranium resources.
  • Alta Mesa Plant (ISR) is located on over 200,000 acres of private land in Texas. The fully licensed and constructed ISR project has a total operating capacity of 1.5 million pounds of uranium per year and produced nearly 5 million pounds of U3O8 between 2005 and 2013. This low-cost production facility is currently on standby, maintained in a state of readiness to respond to expected increases in demand.

In addition to being the largest uranium miner in the U.S., Energy Fuels’ overall portfolio also includes a pipeline of high-quality, large-scale exploration and development projects that are permitted or are in advanced stages of permitting, as well as an industry-leading U.S. NI 43-101 Mineral Resource portfolio.

FACTOID: Energy Fuels has led industry efforts over the past two-plus years to get the U.S. government to recognize the importance of domestically produced uranium, including the 2018 – 2019 Uranium Section 232, the ongoing Nuclear Fuel Working Group and the recently announced creation of the U.S. strategic uranium reserve. The U.S. is by far the largest consumer of uranium in the world, yet we import almost all of our requirements; Energy Fuels aims to change that.

Nuclear Market Potential

Multiple studies in top scientific journals have shown that nuclear power is cleanest and most economical way to produce reliable electricity as worldwide demand continues to soar. Nuclear power is presently the only available and affordable low-carbon power source that can meet both current and future baseload electricity demands while simultaneously reducing air pollution and mitigating climate change. U.S. nuclear power plants currently generate nearly 20% of the nation’s electricity overall and 55% of its carbon‐free electricity and even a modest increase in electricity demand would require significant new nuclear capacity by 2025. According to the World Nuclear Association (WNA), there are currently 441 operable reactors, with another 54 units under construction and 439 in various stages of planning; in addition, the WNA has identified a potentially massive supply/demand gap through 2040 of 1 billion pounds. These factors among others are expected to significantly drive increased demand for uranium.

Reasons Nuclear is Gaining Traction

  • Nuclear reactors emit no greenhouse gases during operation. Over their full lifetimes, they result in comparable emissions to renewable forms of energy such as wind and solar.
  • Unlike any other form of energy, the waste from nuclear energy is contained and managed securely. Used fuel is currently being safely stored for ultimate disposal or future reprocessing, and 96% of this waste can potentially be recycled.
  • Greater demand for clean electricity to power everything from homes to automobiles, reducing dependence on fossil fuels.

No. 1 U.S. Producer of Vanadium in 2019

Energy Fuels also produces vanadium as a byproduct of uranium production. Vanadium is designated a critical mineral, essential to the economic and national security of the United States. Energy Fuels was the largest producer of vanadium in the U.S. in 2019, and has significant high-grade, in-ground vanadium resources, as well as a separate high-purity vanadium production circuit at their White Mesa Mill, which is also the only conventional vanadium mill in the country. Crucial for use in the steel, aerospace, and chemical industries, vanadium plays a critical role in the production of high-strength and light-weight metallic alloys and demand is expected to increase across the globe.

Energy Fuels has several fully permitted and developed standby mines containing large quantities of high-grade vanadium, along with uranium, including:

  • La Sal Complex (Utah)
  • Whirlwind Mine (Colorado/Utah)
  • Rim Mine (Colorado)

Vanadium has also gained increased attention as a catalyst in next-generation high-capacity, “community-scale” batteries used for energy storage generated from renewable sources. Demand is only expected to grow as this market expands. With recent upgrades in its vanadium production operations, in 2019 Energy Fuels produced commercial levels of the highest purity (99.7%) vanadium in the mill’s history and can rapidly adjust production to meet volatile market conditions. Energy Fuels is one of the very few known avenues that provides investors access the vanadium market.

Rare Earth Element (REE) Production, Alternate Feed Material Recycling, and Land Cleanup

The White Mesa Mill also provides the company with diverse cashflow generating opportunities. Security of supply for Rare Earth Elements (REEs) supporting U.S. military and defense requirements is a major issue today. Energy Fuels has been approached by a number of entities, including the U.S. government, inquiring about the potential to process certain REEs at the mill. The White Mesa Mill is currently licensed to process certain REEs, including tantalum and niobium. And, early indications are that the mill can be utilized to produce several other REEs. The White Mesa Mill is also the only facility in North America licensed and capable of recycling alternate feed materials (AFMs). AFMs are essentially low-level waste materials that contain recoverable quantities of natural (or unenriched) uranium. The Company typically generates between $5 and $15 million per year from AFM recycling. Finally, Energy Fuels is seeking to become involved in the cleanup of legacy Cold War era uranium mines in the Four Corners region of the U.S., including on the Navajo Nation. The U.S. Environmental Protection Agency (EPA) has access to over $1.5 billion for the cleanup of just a fraction of the sites on the Navajo Nation. The White Mesa Mill is fully licensed to receive much of this material, we are one of the government’s lowest cost options, and we have the ability to recycle the material and produce usable uranium from it.

Management Team

Mark S. Chalmers, President and CEO
Mark S. Chalmers is the president and chief executive officer of Energy Fuels, a position he has held since Feb. 1, 2018, following his role as chief operating officer of Energy Fuels from July 1, 2016 – Jan. 31, 2018. From 2011 to 2015, Chalmers served as executive general manager of Production for Paladin Energy Ltd., a uranium producer with assets in Australia and Africa, including the Langer Heinrich and Kayelekera mines where, as head of operations, he oversaw sustained, significant increases in production while reducing operating costs. He also possesses extensive experience in in situ recovery (“ISR”) uranium production, including management of the Beverley Uranium Mine owned by General Atomics (Australia), and the Highland mine owned by Cameco Corporation (USA). Chalmers has also consulted to several of the largest players in the uranium supply sector, including BHP Billiton, Rio Tinto, and Marubeni, and until recently served as the chair of the Australian Uranium Council, a position he held for 10 years. Chalmers is a registered professional engineer and holds a Bachelor of Science in Mining Engineering from the University of Arizona.

W. Paul Goranson, COO
W. Paul Goranson is the chief operating officer for Energy Fuels. Goranson has 30 years of mining, processing and regulatory experience in the uranium extraction industry that includes both conventional and in-situ recovery (“ISR”) mining, and he is a registered professional engineer. Prior to the acquisition by Energy Fuels of Uranerz Energy Corporation, Goranson served as president, chief operating officer and director for Uranerz, where he was responsible for operations of the Nichols Ranch ISR Uranium Project. In addition to those duties, he also managed uranium marketing, regulatory and government affairs, exploration and land. Prior to joining Uranerz, Goranson served as president of Cameco Resources, where he led the operations at the Smith Ranch-Highland, Crow Butte and North Butte ISR uranium recovery facilities. Goranson also served as vice president of Mesteña Uranium LLC, and he has served in senior positions with Rio Algom Mining, (a subsidiary of BHP Billiton), and Uranium Resource Inc. Goranson has a Bachelor of Science in Natural Gas Engineering from Texas A&I University, and a Master of Science in Environmental Engineering from Texas A&M University-Kingsville.

David C. Frydenlund, CFO, General Counsel, Corporate Secretary
David C. Frydenlund is chief financial officer, general counsel, and corporate secretary of Energy Fuels. His responsibilities include oversight of all legal matters relating to the company’s activities. His expertise extends to NRC, EPA, state and federal regulatory and environmental laws and regulations. From 1997 to 2012, Frydenlund was vice president of regulatory affairs, general counsel and corporate secretary of Denison Mines Corp., and its predecessor International Uranium Corporation (“IUC”). He also served as a director of IUC from 1997 to 2006 and CFO of IUC from 2000 to 2005. From 1996 to 1997, Frydenlund was vice president of the Lundin Group of international public mining and oil and gas companies, and prior thereto was a partner with the Vancouver law firm of Ladner Downs (now Borden Ladner Gervais) where his practice focused on corporate, securities and international mining transactions law. Frydenlund holds a bachelor’s degree in business and economics from Simon Fraser University, a master’s degree in economics and finance from the University of Chicago and a law degree from the University of Toronto.

Curtis H. Moore, Vice President of Marketing and Corporate Development
Curtis H. Moore is the vice president of Marketing and Corporate Development for Energy Fuels. He oversees product marketing for Energy Fuels, and is closely involved in mergers & acquisitions, investor relations, public relations, and corporate legal. He has been with Energy Fuels for over 12 years, holding various roles of increasing responsibility. Prior to joining Energy Fuels, Moore worked in multi-family real estate development, government relations and public affairs, production homebuilding, and private law practice. Moore is a licensed attorney in the State of Colorado. He holds Juris Doctor and MBA degrees from the University of Colorado at Boulder, and a Bachelor of Arts dual degree in Economics-Government from Claremont McKenna College in Claremont, California.

Energy Fuels Inc. (UUUU), closed Thursday's trading session at $5.15, off by 0.770713%, on 1,042,908 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $4.69/$9.85.

Recent News

Canada Nickel Company Inc. (TSX.V: CNC) (OTCQX: CNIKF)

The QualityStocks Daily Newsletter would like to spotlight Canada Nickel Company Inc. (TSX.V: CNC) (OTCQX: CNIKF).

Canada Nickel Company Inc. (TSX.V: CNC) (OTCQX: CNIKF) highlighted.THE Mining Investment Event of the North ("THE Event"), Québec City, June 19-21, 2023 to be held atthe Fairmont le Château Frontenac and Voltigeurs de Québec Armoury,is pleased to announce that 100+ companies will participate at THEEvent representing all commodities with a focus on criticalmetals. THE Agenda is now available along with information onPanels, Speakers, Participating Companies, and Initiatives.

Canada Nickel Company Inc. (TSX.V: CNC) (OTCQX: CNIKF) is advancing the next generation of nickel-cobalt sulfide projects to deliver the metals needed to power the electric vehicle (EV) revolution and feed the high growth stainless steel market. The company is one of only a few new sources of potential supply outside Indonesia and China.

Canada Nickel possesses industry leading nickel expertise and is focused on low risk, well established mining jurisdictions. The company has launched wholly owned subsidiary NetZero Metals Inc. to develop zero-carbon production of nickel, cobalt and iron and has applied in multiple jurisdictions to trademark the terms NetZero Nickel, NetZero Cobalt and NetZero Iron. Canada Nickel is also pursuing development of processes to allow net zero carbon production of these elements.

Canada Nickel is currently anchored by its 100% owned flagship Crawford Nickel-Cobalt Sulfide Project with large-scale potential located in the heart of Ontario’s prolific Timmins-Cochrane mining camp, adjacent to major infrastructure.

The company believes the EV industry and many other consumer sectors have an urgent need for zero-carbon metal this decade, not in 20-25 years as contemplated by some resource companies. Canada Nickel also believes that nickel supplies from Indonesia and other Pacific island nations, typically controlled by Chinese-owned companies, are not the answer for batteries needed by GM, Ford and the European automakers working to develop and manufacture EV models.

The company is headquartered in Toronto.

Crawford Nickel-Cobalt Sulfide Project

The Crawford Nickel-Cobalt Sulfide Project is the largest sulfide discovery since the early 1970s and contains the fifth-largest nickel sulfide resource in the world, based on Measured & Indicated resources, according to the latest update. The Crawford project is expected to be one of the largest base metal mines in Canada based on results of a Preliminary Economic Assessment. Early projections by Canada Nickel estimate that the project has the potential to produce 50,000 tons of nickel per year. The company is now in the final stages of completing the project’s feasibility study.

The project is projected to produce 2.8 tons of CO2 per ton of nickel equivalent production, which is 89% lower than the industry average of 34 tons of CO2 per ton of nickel equivalent production.

The company is taking significant steps toward developing the Crawford project as a net zero carbon producer. In addition to harnessing the natural ability of the project’s geology to act as a carbon sink through spontaneous reaction of the host rock once exposed to atmospheric conditions called mineral carbonation, Canada Nickel has discovered a new way to enhance carbon capture, termed In Process Tailings (IPT) Carbonation. This act of conditioning the tailings with a concentrated stream of carbon dioxide before deposition has been demonstrated at lab scale to achieve carbon capture at a rate 8-12 times faster than naturally occurring sequestration, achieving more than 60% of the capture that had previously taken six days.

These latest results move the company further toward production of Net Zero Nickel™ and generation of 21 tonnes of CO2 credits per tonne of nickel, which would produce an estimated average of 710,000 tonnes of CO2 credits annually and 18 million total tonnes of CO2 credits over the expected life of mine. IPT Carbonation does not require complex new technologies and major process modifications and could encourage the development of a net zero carbon industrial cluster centered around the Crawford project.

Canada Nickel in January 2023 announced that its latest test work results support the incorporation of carbon capture and storage into the Crawford project. The company believes that utilization of existing process streams should allow IPT to be efficiently engineered and incorporated into the project’s flowsheet, with an integrated feasibility study for the project expected in the second quarter of 2023.

In December 2022, Canada Nickel announced its engagement on Deutsche Bank Securities Inc. (“Deutsche Bank”) and Scotiabank – two of the world’s leading investment banks with a broad base of mining and industrial expertise – as financial advisors for the equity component of the project financing for the Crawford project. In the same release, the company announced the completion of another significant permitting milestone by filing the detailed project description with the Impact Assessment Agency of Canada. Canada Nickel targets receipt of permits by mid-2025, with construction to immediately follow.

Additional Projects

The Reid Nickel Property is located just 16 kilometers southwest of Crawford, or 37 kilometers northwest of Timmins, and contains an ultramafic body with a target geophysical footprint of 3.9 square kilometers. Preliminary assay results from Canada Nickel’s summer/fall drilling program confirm the presence of mineralized dunite, as well as currently undefined higher-grade sections. Partial assay results confirm expected nickel grades. Nickel mineralization in serpentinized dunite was found in all 16 holes drilled to date.

The Sothman Nickel Property is located 70 kilometers south of Timmins. Five drill holes on the eastern half of the target anomaly confirmed the continuation of ultramafic lithologies, primarily peridotite, with moderate to strong serpentinization and variable amounts of mineralization throughout.

The company in December 2022 announced positive drilling results from its ongoing regional exploration campaign at its Reid and Sothman properties. These latest results continue to reinforce the success of Canada Nickel’s geophysical targeting approach and increase the probability of success at the company’s other 20-plus properties within its 42 square kilometers of geophysical targets.

Building on this momentum, Canada Nickel in December 2022 announced its entry into a deal to acquire a 100% interest in the past producing Texmont property situated between the company’s properties south of Timmins. As noted in the news release, the acquisition of the Texmont property provides near-term smaller scale production potential and is highly complementary to the company’s large-scale Crawford and regional nickel sulphide projects.

Market Opportunity

Global demand leaves the market fundamentally short of nickel in the medium- and long-term. Global primary nickel demand will likely reach 3 million tons in 2022, up from 2.4 million tons in 2020, according to the International Nickel Study Group (INSG).

The INSG says primary nickel production is forecast to hit 3.1 million tons in 2022. Indonesia, the world’s largest nickel miner, halted exports of unprocessed nickel ore in January 2020, due to a government-imposed ban. Indonesia has floated the concept of a nickel cartel whose member nations would exert influence over world nickel supply and prices, similar to OPEC’s pricing power over oil.

Benchmark Minerals, a leading EV supply chain research firm, projects that, by 2035, world demand for nickel will double from current levels to 6 million tons annually. That growing demand represents a need for new nickel production equivalent to 70 mines the size of Canada Nickel’s Crawford Project.

Management Team

Mark Selby is Chairman, CEO and Director of Canada Nickel. He was formerly President and CEO of RNC Minerals, where he led a team that successfully raised over $100 million and advanced the Dumont nickel-cobalt project from initial resource to a fully permitted, construction-ready project. He has held senior management roles with Quadra Mining, Inco and Purolator Courier, and was a partner at Mercer Management Consulting. Since 2001, he has been recognized as one of the leading authorities on the nickel market. He graduated from Queen’s University with a Bachelor of Commerce.

Wendy Kaufman is CFO of Canada Nickel. She has 25 years of experience leading publicly listed mining companies in project financing, capital structuring, capital markets, accounting and internal controls, tax, and financial reporting and public disclosure. She was also previously CFO at Khiron Life Sciences Corp. and held CFO and senior finance positions at Pasinex Resources Limited, Primero Mining Corporation and Inmet Mining Corporation. She holds a Bachelor of Business Administration from Wilfrid Laurier University and is a Chartered Professional Accountant.

Steve Balch is VP Exploration at Canada Nickel. He is an Ontario registered geoscientist with 32 years of experience in geophysics, specializing in magnetic and electromagnetic methods. He founded Triumph Instruments and developed the AirTEM system, a multi-coil helicopter-borne EM system that is in use worldwide. He has also been active in borehole geophysics and helped develop new technologies including north-seeking gyros, temperature compensated induction conductivity probes, UAV-based magnetometers and high sensitivity magnetic gradiometers.

Christian Brousseau is VP Capital Projects at Canada Nickel. He is a professional engineer (P.Eng) with over 30 years of experience in engineering, design and construction in the Canadian mining industry, including six years as Project Director for the Dumont Project and three years as the Engineering and Construction Manager for Detour Gold. Prior to Detour, he held various construction management positions at Osisko’s Malartic Project and at Goldcorp’s Éléonore Project. He also spent eight years at Falconbridge supervising and managing various capital projects.

Canada Nickel Company Inc. (OTCQX: CNIKF), closed Monday's trading session at $2.05, up 3.0151%, on 73,251 volume with 375 trades. The average volume for the last 3 months is 57,207 and the stock's 52-week low/high is $1.04999995/$5.63000011.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announcedthat it has received notifications of four new patents eitherawarded or allowed. In Japan, the company secured a new patentunder its Patent Family #3: Stable Ready-to-Drink BeverageCompositions Comprising Lipophilic Active Agents. This is Lexaria’sfifth awarded patent in Japan, providing strength to its growingJapanese patent portfolio. In Australia, Lexaria has received a newpatent under its Patent Family #18: Compositions and Methods forEnhanced Delivery of Antiviral Agents. This is Lexaria’s 10thpatent in Australia and its second in this patent family. InCanada, Lexaria has been advised of allowance of a new patent underits Patent Family #8: Compositions Infused With Nicotine Compoundsand Methods of Use Thereof. This is Lexaria’s second patent in thisfamily and follows a similar issuance in Australia in 2022. In theUSA, Lexaria has been advised that a new patent under its PatentFamily #21: Compositions and Methods for Treating Hypertension hasbeen allowed. To be the first patent in this family, Lexariabelieves this could be of particular importance related to itspursuit of utilizing DehydraTECH-CBD in relation to its expectedupcoming FDA Investigational New Drug application.

To view the full press release, visit https://ibn.fm/aebe8

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Thursday's trading session at $2.2, off by 1.7857%, on 18,187 volume. The average volume for the last 3 months is 18,174 and the stock's 52-week low/high is $1.80/$4.12.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has releasedtest results from technology acquired through a recent jointventure. According to the announcement, previous vehicle testresults, which were performed by Element Materials Technology, showthat Energy Management module (“EMM”) technology resulted in rangeincrease of 60%–70% along with an increase in efficiency of anycurrent EV battery. In addition to the testing conducted by ElementMaterials, the EMM technology was tested by Mullen Automotiveengineers on Mullen’s class 1 EV cargo van with results indicatinga more than 75% increase in range for vehicle’s 42-kWh lithium-ionbattery pack, which would be a calculated EPA estimated range of186 miles; the added cost and mass would be minimal. Mullenindicated that the EMM technology is being integrated into productdevelopment, and the company anticipates the tech will beincorporated in all Mullen commercial and consumer vehicleprograms. In addition, the company has filed a U.S. provisionalpatent application covering the technology. Element MaterialsTechnology is a global leader of testing, inspection andcertification with more than 200 testing labs worldwide. “Seeingthe previous EMM test results conducted by Element, along withGlobal EVT testing, and correlating that with testing by ourengineers, we believe this technology is a perfect fit for Mullen’sEV product lineup as well as the advancement in EV technology forthe overall automotive industry,” said Mullen Automotive CEO andchair David Michery in the press release. “Mullen Advanced EnergyOperations plans on licensing this technology to anyone who uses anelectric vehicle.”

To view the full press release, visit https://ibn.fm/KkhnC

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Thursday's trading session at $0.0847, off by 5.7842%, on 235,873,957 volume. The average volume for the last 3 months is 195.47M and the stock's 52-week low/high is $0.08/$1.71.

Recent News

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)

The QualityStocks Daily Newsletter would like to spotlight BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV).

The company’s highly experienced and successful pharmaceuticalindustry leadership team includes former senior executives fromNovartis, GSK, and Bristol-Myers Squibb

The team has executed eight clinical trials, including aseven-country, 12,400-participant Phase 3 trial of a priorinfluenza candidate, and built, owns, and operates its GMPbiologics manufacturing facility

BiondVax has an exclusive collaboration with the prestigious MaxPlanck Institute for Multidisciplinary Sciences (“MPG”) and theUniversity Medical Center Göttingen (“UMG”), to develop a pipelineof innovative nanosized antibody therapies

BiondVax’s experience, assets, and pipeline represent a rareopportunity for a company of its size

BiondVax Pharmaceuticals (NASDAQ: BVXV), a Jerusalem-based biotechnology company, is laser focused ondeveloping, manufacturing, and commercializing innovative NanoAbimmunotherapeutic products, primarily for treating infectious andautoimmune diseases. Collaborating with the prestigious Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen (“UMG”), both inGermany, BiondVax is developing a pipeline of nanosized antibody(NanoAb) therapies addressing diseases underserved by currenttreatments and with large and growing markets, such as COVID-19,asthma and psoriasis.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, BiondVax is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. BiondVax is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, BiondVax has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, BiondVax signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. BiondVax anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of BiondVax’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

BiondVax has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, BiondVax will focus development efforts beginning with the following NanoAbs:

  • NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
  • NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. BiondVax anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future BiondVax drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is BiondVax’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Chief Engineer and Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at BiondVax. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at BiondVax. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining BiondVax, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at BiondVax. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to BiondVax through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), closed Thursday's trading session at $1.99, off by 7.0093%, on 36,380 volume. The average volume for the last 3 months is 36,227 and the stock's 52-week low/high is $1.70/$17.60.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.